[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-induced-parkinsonism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-induced-parkinsonism":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100648085","a-computer-assisted-tool-for-objective-assessment-of-extrapyramidal-symptoms-100648085",false,"NCT07715994","A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms","Development of an Objective Quantitative Assessment and Computer-Assisted Diagnostic Tool for Extrapyramidal Symptoms","Inclusion Criteria\n\nA. Control Group\n\n1. Aged 18 to 80 years, with no restriction on sex.\n2. No current or past history of a psychiatric disorder meeting ICD-10 or DSM-5 criteria.\n3. No current or past history of central nervous system disease, such as primary Parkinson's disease or epilepsy, and no severe physical illness.\n4. No use within the 3 months before screening of medications that may cause extrapyramidal symptoms, such as antipsychotics or certain antiemetic medications.\n5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence.\n6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written informed consent.\n\nB. EPS Disease Group\n\n1. Aged 18 to 80 years, with no restriction on sex.\n2. Diagnosis of schizophrenia or a related psychotic disorder according to ICD-10 criteria.\n3. Regular treatment with one or more antipsychotic medications for at least 4 weeks.\n4. Clinically confirmed antipsychotic-induced extrapyramidal symptoms meeting at least one of the following criteria:\n\n   1. Drug-induced parkinsonism: a total score of 2 or higher on Items 1, 2, 3, 4, 5, and 9 of the Simpson-Angus Scale (SAS).\n   2. Akathisia: a score of 2 or higher on the Global Clinical Assessment item of the Barnes Akathisia Rating Scale (BARS).\n   3. Tardive dyskinesia: a score of 3 or higher on any one of Items 1 through 7 of the Abnormal Involuntary Movement Scale (AIMS), or a score of 2 or higher on any two of these items.\n5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence.\n6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written informed consent by the participant or, where applicable, the participant's legal guardian.\n\nExclusion Criteria\n\nThe following exclusion criteria apply to both groups:\n\n1. Primary neurological or organic movement disorders that may affect the assessment results, such as primary Parkinson's disease, Huntington's disease, Wilson's disease, or sequelae of stroke.\n2. Severe musculoskeletal disease, recent fracture, limb disability, or other physical conditions that prevent completion of the required assessment tasks.\n3. Acute exacerbation of psychiatric symptoms with severe agitation, impulsivity, stupor, or severe cognitive impairment that prevents safe and adequate cooperation with the assessment.\n4. Severe deformity of the face or tested limbs, large dark-colored tattoos, or severe non-removable occlusion that may substantially interfere with computer-vision-based assessment.\n5. Poorly fitting removable dentures or frequent compensatory oral movements that may interfere with objective assessment of orofacial movements.\n6. Any condition that, in the investigator's judgment, may affect participant safety, substantially compromise data quality, or make the individual unsuitable for participation.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},180,"ESTIMATED","OBSERVATIONAL","This prospective, single-center observational study aims to develop and validate a computer-assisted tool for the objective quantitative assessment of extrapyramidal symptoms (EPS).\n\nThe study will enroll 180 participants, including 90 healthy controls and 90 participants with clinically confirmed antipsychotic-induced EPS. The healthy control group will provide reference data on normal movement, while the EPS disease group will provide data on abnormal movements associated with drug-induced parkinsonism, akathisia, or tardive dyskinesia.\n\nEach participant will complete one study visit lasting approximately 60 minutes. During the visit, a trained psychiatrist will assess EPS using the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS). Participants will also complete standardized movement tasks while a non-contact computer vision system records and analyzes movement features. The device-based assessment will be repeated after a short rest to evaluate the stability of the measurements.\n\nData collected earlier in the study will be used to develop and optimize the assessment tool. After the algorithm is finalized and locked, data from subsequently enrolled participants will be used for independent validation. The study will evaluate how closely the tool's results agree with clinician assessments, as well as its ability to identify EPS, produce stable repeated measurements, and operate feasibly and safely in a clinical setting.\n\nThis is an observational study. The study does not assign treatment, change participants' medications, or use the investigational tool to make treatment decisions.",[26,27,28,29],"Extrapyramidal Symptoms","Drug-induced Parkinsonism","Akathisia, Drug-Induced","Tardive Dyskinesia (TD)",[31,32,33,34],"Antipsychotic-Induced Extrapyramidal Symptoms","Objective Quantitative Assessment","Computer-Assisted Diagnosis","Computer Vision","NOT_YET_RECRUITING","2026-07-20",{"date":38,"type":39},"2026-07-21","ACTUAL",{"date":41,"type":22},"2026-07",{"date":43,"type":22},"2027-04",{"name":45,"class":46},"Shanghai Mental Health Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100589088","ai-enhanced-optimization-of-acute-levodopa-challenge-test-100589088","NCT06949865","AI-Enhanced Optimization of Acute Levodopa Challenge Test","Clinical Research on Optimization of Acute Levodopa Challenge Test and Exploration of New Motor Paradigm Based on the Integration of Perception Technology and Artificial Intelligence","Inclusion Criteria:\n\n1. Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.\n2. Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n3. Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n4. Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n5. Drug-induced parkinsonism (DIP) group: 1. Parkinsonism; 2. Drug history, the appearance of symptoms is related to specific drugs; 3. Symptoms are reversible, and the symptoms are reduced or disappeared when the corresponding drugs are reduced; 4. Rule out other causes; 5. Subjects are 50-75 years old (including boundary values), gender is not limited; 6. Agree to undergo study-related examination evaluation and sign informed consent.\n6. Corticobasal degeneration (CBD) group: 1. Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n7. Dementia with Lewy Bodies (DLB) Group: 1. Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria. 2. Exhibits symptoms of Parkinsonism. 3. Subjects are aged 50-75 years (inclusive), with no gender restriction. 4. Agree to undergo study-related assessments and evaluations and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Cognitive dysfunction, unable to complete the study (MMSE \\\u003C 23)\n2. Inability to tolerate levodopa shock test\n3. Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases\n4. Those with serious behavioral problems or mental disorders\n5. Inability to sign informed consent\n6. Other conditions that are considered unsuitable by the investigator to participate in this study.","50 Years","75 Years",{"count":58,"type":22},2000,"A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.",[61,27,62,63,64,65,66],"Vascular Parkinsonism","Corticobasal Degeneration (CBD)","Parkinson Disease (PD)","Dementia With Lewy Body Disease","Progressive Supranuclear Palsy(PSP)","Multiple System Atrophy (MSA)","RECRUITING","2025-04-22",{"date":70,"type":39},"2025-04-29",{"date":72,"type":39},"2024-05-28",{"date":74,"type":22},"2026-12-31",{"name":76,"class":46},"Beijing Tiantan Hospital","Drug Induced Parkinsonism"]